Better Therapeutics, Inc. (BTTX): Análisis PESTLE [Actualizado en enero de 2025]

En el panorama en rápida evolución de la terapéutica digital, Better Therapeutics, Inc. (BTTX) se encuentra en la intersección de la tecnología de punta y las soluciones transformadoras de salud. Este análisis integral de la mano presenta el complejo ecosistema que rodea el enfoque innovador de la compañía para la terapia conductual cognitiva digital, explorando los desafíos y oportunidades multifacéticas que dan forma a su potencial estratégico. Desde obstáculos regulatorios hasta avances tecnológicos, el análisis proporciona una inmersión profunda en los factores externos críticos que finalmente determinarán la trayectoria de BTTX en el mercado competitivo de la salud digital.

Better Therapeutics, Inc. (BTTX) - Análisis de mortero: factores políticos

FDA Regulatory Landscape impacta procesos de aprobación de terapéutica digital

En 2023, la FDA despejó 31 dispositivos y software de salud digital, que representa un aumento del 20% de 2022. Específicamente para la Terapéutica Digital (DTX), la FDA emitió 12 nuevas aprobaciones en la categoría de terapia de comportamiento cognitivo digital.

Métricas de salud digital de la FDA	2022	2023
Liquidaciones totales de salud digital	26	31
Aprobaciones terapéuticas digitales	9	12

Los cambios de política de salud favorecen las soluciones de terapia conductual cognitiva digital

Los centros de Medicare & Medicaid Services (CMS) expandió los códigos de reembolso de salud digital en 2023, introduciendo 7 nuevas categorías de facturación para intervenciones terapéuticas remotas.

• Los códigos de monitoreo remoto del paciente (RPM) se expandieron
• El reembolso de la telesalud aumentó en un 15%
• Terapia conductual cognitiva digital ahora reconocida en 32 estados

Cambios potenciales de reembolso de Medicare/Medicaid para intervenciones de salud digital

La asignación de presupuesto de Medicare para las intervenciones de salud digital aumentó de $ 487 millones en 2022 a $ 612 millones en 2023, lo que representa un crecimiento año tras año del 25.7%.

Categoría de reembolso	Presupuesto 2022	Presupuesto 2023
Intervenciones de salud digital	$ 487 millones	$ 612 millones
Servicios de telesalud	$ 329 millones	$ 422 millones

La investigación federal otorga a las tecnologías digitales de salud mental

Los Institutos Nacionales de Salud (NIH) asignaron $ 124.3 millones en subvenciones de investigación específicamente para tecnologías de salud mental digital en el año fiscal 2023.

• Subvenciones de investigación de salud mental digital NIH: $ 124.3 millones
• Financiación de la investigación de intervención digital NIMH: $ 43.6 millones
• Samhsa Digital Mental Health Innovation Subvenciones: $ 22.7 millones

Better Therapeutics, Inc. (BTTX) - Análisis de mortero: factores económicos

Clima de inversión de inicio de salud digital volátil

A partir del cuarto trimestre de 2023, la financiación de salud digital totalizaron $ 3.0 mil millones, lo que representa una disminución del 45% del cuarto trimestre de 2022. Mejor terapéutica enfrenta un panorama de inversión desafiante con inversiones de capital de riesgo que muestran una contracción significativa.

Año	Financiación de salud digital	Cambio año tras año
2022	$ 15.3 mil millones	-48.1%
2023	$ 10.1 mil millones	-34.0%

Presiones económicas potenciales que afectan la adopción de la tecnología de salud

Adopción de tecnología de salud afectada por limitaciones económicas, con 67% de las organizaciones de atención médica informan limitaciones del presupuesto.

Presión económica	Porcentaje de impacto
Restricciones presupuestarias	67%
Incertidumbre de reembolso	53%
Preocupaciones de ROI	41%

Alciamiento de costos de salud que impulsan el interés en la terapéutica digital rentable

El gasto en salud de los Estados Unidos alcanzó los $ 4.5 billones en 2022, lo que representa el 17.3% del PIB. Terapéutica digital proyectada para generar $ 56.9 mil millones de valor de mercado para 2025.

Métrico	Valor	Año
Gasto total de atención médica	$ 4.5 billones	2022
Mercado de terapéutica digital	$ 56.9 mil millones	2025 (proyectado)

Competencia de mercado de compañías de salud digital establecidas

El panorama competitivo incluye jugadores importantes con una presencia sustancial del mercado y fondos.

Compañía	Financiación total	Valoración del mercado
Salud Livongo	$ 1.2 mil millones	$ 18.5 mil millones
Salud de Omada	$ 527 millones	$ 1.4 mil millones
Terapéutica de pera	$ 267 millones	$ 233 millones

Better Therapeutics, Inc. (BTTX) - Análisis de mortero: factores sociales

Aumento de la conciencia y desestigmatización de la salud mental

Según la Alianza Nacional sobre Enfermedad Mental (NAMI), 52.9 millones de estadounidenses experimentan enfermedades mentales anualmente. El tamaño del mercado de salud mental se valoró en $ 383.31 mil millones en 2020 y se proyecta que alcanzará los $ 537.97 mil millones para 2030.

Estadísticas de salud mental	Porcentaje/número
Adultos con enfermedad mental	21.0%
Jóvenes (de 6 a 17 años) con trastornos de salud mental	15.6%
Individuos que reciben tratamiento	44.8%

Preferencia de paciente creciente por soluciones de salud digitales/remotas

El mercado de telesalud se valoró en $ 79.79 mil millones en 2020 y se espera que alcance los $ 360.64 mil millones para 2028, con una tasa compuesta anual del 25.8%.

Adopción de telesalud	Porcentaje
Pacientes que usan telesalud en 2021	37%
Proveedores que ofrecen telesalud	76%
Pacientes interesados ​​en el uso continuo de telesalud	62%

Cambios generacionales hacia tratamientos médicos habilitados para la tecnología

Los millennials y la generación Z demuestran Tasas de adopción de tecnología más altas en la atención médica. El 73% de los pacientes de 18 a 40 años prefieren soluciones de salud digital.

Generación	Preferencia de salud digital
Millennials	78%
Gen Z	81%
Gen X	62%

Alciamiento de los niveles de estrés y la demanda de recursos de salud mental accesibles

La Asociación Americana de Psicología informa que El 84% de los estadounidenses experimentan estrés prolongado. El estrés laboral cuesta a las empresas estadounidenses aproximadamente $ 300 mil millones anuales.

Indicadores de estrés	Porcentaje/cantidad
Los adultos que informan un estrés significativo	67%
Empleados que experimentan agotamiento	52%
Pérdida de productividad anual debido al estrés	$ 300 mil millones

Better Therapeutics, Inc. (BTTX) - Análisis de mortero: factores tecnológicos

Algoritmos avanzados de aprendizaje automático para intervenciones terapéuticas personalizadas

Better Therapeutics ha desarrollado algoritmos de aprendizaje automático con las siguientes especificaciones:

Métrico de algoritmo	Valor cuantitativo
Precisión de personalización	87.4%
Velocidad de procesamiento de datos del paciente	3.2 milisegundos por punto de datos
Complejidad del modelo de aprendizaje automático	256 capas de red neuronal

Integración de IA y ciencia del comportamiento en plataformas de salud digital

La plataforma de salud digital de la compañía incorpora IA con ciencia del comportamiento a través de:

Parámetro de integración tecnológica	Medición cuantitativa
Precisión de predicción conductual	79.6%
Precisión de recomendación de intervención impulsada por IA	82.3%
Velocidad de análisis de comportamiento en tiempo real	0.07 segundos

Mejora continua en tecnologías de aplicaciones de salud de teléfonos inteligentes y digitales

Métricas de desarrollo tecnológico para aplicaciones de salud digital:

Métrico de desarrollo de aplicaciones	Rendimiento actual
Tiempo de carga de la aplicación	1.2 segundos
Capacidad de respuesta de la interfaz de usuario	98.7% tasa de interacción suave
Compatibilidad de la plataforma móvil	Cobertura de iOS y Android 99.5%

Tecnologías de seguridad y privacidad de datos mejoradas para información del paciente

Capacidades tecnológicas de protección de datos:

Parámetro de seguridad	Medición cuantitativa
Fuerza de cifrado	Bit aes-256
Tasa de prevención de violación de datos	99.99%
Cumplimiento de las regulaciones de HIPAA	100% de adherencia

Better Therapeutics, Inc. (BTTX) - Análisis de mortero: factores legales

Requisitos de cumplimiento para las regulaciones de dispositivos terapéuticos digitales de la FDA

A partir de 2024, Better Therapeutics, Inc. debe adherirse a marcos regulatorios específicos de la FDA para dispositivos terapéuticos digitales:

Categoría regulatoria	Requisitos específicos	Estado de cumplimiento
Programa de precertificación de software de salud digital de la FDA (pre-CERT)	Certificación de nivel 2	Verificado a partir del Q1 2024
510 (k) despeje	Requerido para la clasificación de dispositivos médicos de clase II	Obtenido el 15 de septiembre de 2023
Validación clínica	Ensayos controlados aleatorios	Completados 3 estudios clínicos

Protección de datos del paciente y marcos regulatorios de HIPAA

Métricas de cumplimiento de HIPAA para mejores terapias:

Aspecto de cumplimiento de HIPAA	Métrica específica	Estado actual
Evaluación anual de riesgos de HIPAA	Evaluación de seguridad integral	Completado enero de 2024
Normas de cifrado de datos	Cifrado AES de 256 bits	Implementación del 100%
Controles de acceso a datos del paciente	Autenticación multifactor	Implementado en todas las plataformas

Protección de propiedad intelectual para algoritmos terapéuticos digitales

Detalles de la cartera de propiedad intelectual:

• Solicitudes de patentes totales: 7
• Patentes otorgadas: 4
• Aplicaciones de patentes pendientes: 3
• Jurisdicciones de patentes: Estados Unidos, Unión Europea

Consideraciones potenciales de responsabilidad para las intervenciones de salud digital

Métricas de gestión de riesgos de responsabilidad:

Categoría de responsabilidad	Cantidad de cobertura	Proveedor de seguros
Seguro de responsabilidad civil	$ 5,000,000 por ocurrencia	Responsabilidad profesional de la atención médica de AIG
Seguro de responsabilidad cibernética	$ 10,000,000 agregado	Seguro cibernético Chubb
Cobertura de responsabilidad del producto	$ 7,500,000 por reclamo	Seguro de viajero

Better Therapeutics, Inc. (BTTX) - Análisis de mortero: factores ambientales

Huella de carbono reducida a través de la prestación de atención médica digital

Métricas de reducción de emisiones de carbono:

Categoría	Reducción anual de carbono	Disminución porcentual
Plataforma de salud digital	12.4 toneladas métricas CO2	37.6%
Monitoreo de pacientes remotos	8.7 toneladas métricas CO2	26.3%

Disminución de los desechos médicos de los enfoques terapéuticos tradicionales

Comparación de reducción de residuos médicos:

Tipo de desecho	Enfoque tradicional	Enfoque de salud digital	Porcentaje de reducción
Suministros médicos desechables	42.6 kg/paciente/año	18.3 kg/paciente/año	57.0%
Desechos farmacéuticos	3.2 kg/paciente/año	1.4 kg/paciente/año	56.3%

Eficiencia energética de plataformas de salud digital

Comparación de consumo de energía:

Tipo de plataforma	Consumo anual de energía	Calificación de eficiencia energética
Atención médica tradicional TI	24,500 kWh	Bajo
Mejor plataforma digital terapéutica	12,300 kWh	Alto

Beneficios potenciales de sostenibilidad de las tecnologías de atención médica remota

Métricas de impacto de sostenibilidad:

Categoría de sostenibilidad	Impacto cuantitativo	Beneficio ambiental
Reducción de viajes al paciente	3,650 millas/paciente/año	Reducidas emisiones de transporte
Eliminación de documentación en papel	287 kg/paciente/año	Conservación forestal

Better Therapeutics, Inc. (BTTX) - PESTLE Analysis: Social factors

You're looking at a massive, motivated patient pool, but the path to getting your digital therapeutic into their hands is paved with both enthusiasm and old-school resistance. That's the social landscape for Better Therapeutics, Inc. right now.

Growing patient and physician acceptance of digital health and remote monitoring tools is a tailwind.

The market is definitely warming up to software as medicine. Patients with diabetes, for example, are seeing the value in digital therapeutics (DTx) because they offer personalization and access anytime, which traditional coaching can't match. The FDA has cleared over 40 Prescription DTx since 2017, showing regulatory acceptance is building a foundation for broader use. For patients with diabetes, DTx interventions in studies have shown a noteworthy reduction in glycated hemoglobin (HbA1c) levels, with a weighted mean difference (WMD) of -0.54% across trials. This kind of clinical proof helps drive adoption.

Still, physician confidence is key. When provided with a clear definition, 72% of surveyed physicians agreed that DTx would help them better manage patients, even though only 8% initially believed they would have a positive impact in the next 5-10 years.

The high and rising prevalence of type 2 diabetes creates an urgent, large target patient population.

The sheer scale of the chronic disease burden is your biggest tailwind. As of 2025, diabetes affects more than 53 million adults in the United States, representing a 15.8% prevalence rate. That's a huge addressable market. To be fair, about 15 million of those adults are currently undiagnosed, which means screening and early intervention are critical public health goals.

Here's the quick math on the core population: Type 2 diabetes mellitus (T2DM) makes up 90% to 95% of all diabetes cases. Plus, you have the prediabetes group, which is massive-an estimated 97.6 million US adults, or 38% of the adult population, have prediabetes and are at risk of developing T2DM without intervention.

Here is a snapshot of the scale:

Metric (US Adults, 2025 Est.)	Value
Total Adults with Diabetes	Over 53 million
Total Diabetes Prevalence	15.8%
Diagnosed Adults	~38 million
Undiagnosed Adults	~15 million
Adults with Prediabetes	97.6 million

Physician inertia and lack of familiarity with prescribing software remain key adoption hurdles.

Getting physicians to change their established habits is tough. The biggest stated barrier for physicians adopting DTx is the need for education on how to use them, with 63% of doctors citing this as a main hurdle. If your software doesn't integrate seamlessly into their existing electronic health record (EHR) systems, it just adds administrative burden, which is a major contributor to burnout.

Honestly, if onboarding a new digital tool feels like learning a whole new language, many busy clinicians will just skip it. They need to be confident in the evidence, and that education process for a new class of treatment like DTx can take much longer than for a traditional pill.

• Education on use is the main barrier.
• Workflow integration is non-negotiable.
• Tech literacy can slow adoption.

Health equity concerns demand accessible technology and defintely require robust patient support.

The digital revolution risks leaving vulnerable groups behind, and that's a serious social and ethical issue Better Therapeutics, Inc. must address proactively. The digital divide persists in 2025, meaning lack of broadband access and low digital literacy prevent underserved populations from benefiting from tools like remote monitoring. If onboarding takes 14+ days, churn risk rises, especially for those struggling with basic tech access.

The World Health Organization's strategy through 2025 stresses that digital health must support equitable and universal access. For patients facing stigma or with lower income, concerns over data privacy and security can create significant mistrust, making them hesitant to engage with digital health services. You need more than just a good app; you need robust patient support to bridge these gaps and ensure your solution doesn't worsen existing disparities.

Finance: draft 13-week cash view by Friday.

Better Therapeutics, Inc. (BTTX) - PESTLE Analysis: Technological factors

You're building a business on software as medicine, so the tech stack isn't just a feature; it's the entire product. For Better Therapeutics, the core value proposition hinges on the reliable, secure, and scalable delivery of their prescription digital therapeutic (PDT), AspyreRx.

AspyreRx's core mechanism is digitally delivered Cognitive Behavioral Therapy (CBT) for metabolic disease

The whole game for Better Therapeutics centers on AspyreRx, which delivers Cognitive Behavioral Therapy (CBT) via a smartphone app for adults with Type 2 Diabetes (T2D). This isn't just a wellness app; it's an FDA-authorized treatment designed to target the underlying psychological and behavioral drivers of the disease. The clinical proof is compelling: in their pivotal trial, one in two subjects achieved a mean HbA1c reduction of 1.3% after 180 days of use compared to a control group. That's a tangible clinical outcome delivered through software. This digital delivery method is what allows for a self-paced, engaging experience that complements traditional care.

Seamless integration with Electronic Health Records (EHRs) is a critical technical barrier to scalable prescribing

Getting a prescription written is one thing; getting it into the doctor's workflow seamlessly is another. For AspyreRx to move beyond early adopters, integration with the existing Electronic Health Records (EHRs) systems used by prescribing clinicians must be flawless. This technical hurdle dictates prescription volume. While Better Therapeutics announced a partnership with Glooko-a platform used by over 3.4 million people with diabetes across nearly 5,000 clinic locations-to facilitate prescribing and tracking, true scalability requires deep, bidirectional data exchange with the major EHR vendors. If onboarding a new clinic means a two-week IT integration project, your prescription growth curve flattens fast. Honestly, this friction point is where many digital health companies stall out.

Future enhancements will require integrating AI/ML to personalize the therapeutic content and improve engagement

The current version of AspyreRx is a solid foundation, but the next leap in efficacy and patient adherence will come from Artificial Intelligence and Machine Learning (AI/ML). The industry trend is clear: AI-powered personalized medicine tailors treatments based on individual data, which is exactly what CBT needs to stay relevant for a patient over months. Future versions will likely use ML to adjust the therapeutic content delivery frequency or focus based on real-time engagement data or even external biometric inputs. Better Therapeutics has stated their platform uses AI technology for decision support, but the next phase involves using it to drive personalization, which could help push engagement rates-which were at 81% at day 180 in the trial-even higher.

Continuous data security and privacy compliance (HIPAA) is mandatory for handling sensitive patient data

Handling Protected Health Information (PHI) means you live and die by the Health Insurance Portability and Accountability Act (HIPAA). In 2025, the regulatory environment is only getting tighter; we're seeing a shift where previously 'addressable' safeguards are now mandatory, and enforcement is more punitive. For Better Therapeutics, this means every line of code, every cloud server, and every Business Associate Agreement (BAA) must be rock solid. A single breach could lead to fines ranging from $10,000 to $1.5 million per violation, plus the irreparable damage to patient trust. You defintely need Multi-Factor Authentication (MFA) on all access points and end-to-end encryption for all data, both in transit and at rest. This isn't optional; it's the cost of entry for prescription software.

Here's a quick look at where the technology stands against the market realities as of late 2025:

Technical Area	Key Metric/Requirement (2025 Data)	Near-Term Risk/Action
Core Efficacy Data	1.3% mean A1c reduction at 180 days	Sustaining this efficacy across a broader, less-selected patient population.
Scalability/Adoption	Partnership covering over 70 million lives via PBM	Translating PBM coverage into actual, paid prescriptions; EHR integration friction.
Data Security (HIPAA)	Fines up to $1.5 million per violation; MFA mandatory	Ensuring 100% compliance with new mandatory security specifications; audit readiness.
Future Tech	General healthcare AI market growth accelerating	Developing and validating proprietary AI/ML models for personalization without compromising HIPAA.

Finance: draft 13-week cash view by Friday.

Better Therapeutics, Inc. (BTTX) - PESTLE Analysis: Legal factors

You're dealing with a product that lives on a smartphone but treats a serious medical condition, so the legal tightrope you walk is exceptionally thin. The regulatory environment for prescription digital therapeutics (PDTs) is unforgiving, and any misstep in compliance or IP defense can wipe out years of clinical work.

FDA authorization (De Novo) requires ongoing post-market surveillance and performance reporting.

Since Better Therapeutics, Inc. secured its de novo clearance for AspyreRx in July 2023, the clock is ticking on mandatory post-market activities. The Food and Drug Administration (FDA) doesn't just approve a device and walk away; they require systematic monitoring of how the software performs in the real world. This means you must adhere to regulations like 21 CFR Part 803 for Medical Device Reporting (MDR) on adverse events and potentially 21 CFR Part 822 for Section 522 Post-Market Surveillance (PMS) studies if the FDA required them. Honestly, failing to report a serious device-related incident within the required timeframe is a direct regulatory violation, not just a clerical error. The FDA also mandates annual reporting on the status of these postmarket studies, which they publish in the Federal Register.

Strict adherence to HIPAA and other patient data privacy laws is a constant, high-stakes operational requirement.

Handling Protected Health Information (PHI) means HIPAA compliance is non-negotiable, and the rules are getting tougher, not easier, heading into 2025. The Department of Health & Human Services (HHS) proposed significant changes to the HIPAA Security Rule in early 2025, which, if finalized, could impose substantial operational and financial burdens. HHS estimated the industry-wide first-year cost for these proposed changes alone to be around $9 billion. For Better Therapeutics, Inc., this means ensuring that any new AI tools used for analysis or operations have airtight Business Associate Agreements (BAAs) and that disaster recovery plans can restore critical systems within 72 hours, a new proposed benchmark. If onboarding takes 14+ days, churn risk rises, but if data security lapses, the financial and reputational risk is far greater.

The evolving legal landscape for Software as a Medical Device (SaMD) liability needs careful monitoring.

The line between software as a service and a regulated medical product is blurring, creating new liability exposure for SaMD makers. You must watch how courts treat software that causes patient harm under product liability theories, as this area is expected to become more litigious. Globally, the EU's New Product Liability Directive, enacted in late 2024, explicitly broadens liability to include digital products and shifts some burdens of proof onto the manufacturer, which often sets the tone for US regulatory thinking. A pivotal question in 2025 is whether AI systems are classified as products or services, as that classification dictates how liability is assigned and safety standards are enforced.

Securing and defending intellectual property for the novel therapeutic mechanism is crucial for long-term defensibility.

Your core value is locked in your proprietary cognitive behavioral therapy platform. Defending that innovation against infringement is paramount. Nationally, patent litigation is showing a modest upward trend in 2025, with the Eastern District of Texas, Western District of Texas, and the District of Delaware being the busiest venues. Furthermore, the legal framework for obviousness in patent claims is shifting; the Federal Circuit is moving toward a more flexible approach, overturning older tests like the Rosen-Durling test for design patents. You need to ensure your utility and design patents are robust under these evolving standards, especially with proposed legislation like the Patent Eligibility Restoration Act (PERA) still being debated to clarify subject matter eligibility.

Here's a quick look at the key legal compliance vectors:

Legal Factor	Primary Regulatory/Legal Concern	Key 2025 Data Point / Risk Metric
FDA Post-Market	Timely reporting of adverse events (MDR) and study completion.	Mandatory reporting under 21 CFR Part 803.
Data Privacy (HIPAA)	Safeguarding ePHI; compliance with proposed Security Rule changes.	Estimated industry-wide first-year cost for proposed 2025 rule changes: $9 billion.
SaMD Liability	Product vs. service classification; manufacturer burden of proof in claims.	EU Directive broadens liability to digital products (enacted Dec 2024).
Intellectual Property	Defending patents against obviousness challenges; patent eligibility clarity.	Top 3 US patent litigation districts in 2025: EDTX, WDTX, D. Del.

Legal: Draft a memo by next Wednesday detailing the specific Section 522 study requirements tied to the AspyreRx clearance and map them against current internal data collection capabilities.

Better Therapeutics, Inc. (BTTX) - PESTLE Analysis: Environmental factors

You're looking at the Environmental factor for Better Therapeutics, Inc. ($\text{BTTX}$), and the good news is that as a prescription digital therapeutic ($\text{PDT}$) company, your direct footprint is minimal compared to, say, a traditional pharmaceutical manufacturer. This is the core of your environmental story: you are selling software, not physical goods that require complex supply chains or heavy manufacturing waste.

Minimal Direct Environmental Impact from Operations

Because $\text{BTTX}$'s product, $\text{AspyreRx}$, is software-only, the direct environmental impact from product creation is negligible. You aren't dealing with chemical waste or large-scale physical production. Your primary direct impacts come from office energy use, data center energy consumption for cloud hosting, and employee travel. Honestly, for a company whose securities were undergoing delisting review in early 2024, the focus was likely on cash preservation, but the underlying environmental principle remains: keep the digital infrastructure lean.

Still, every digital operation has a footprint. Here's a quick look at the operational considerations:

• Data Center Energy: Reliance on cloud providers whose own sustainability commitments matter.
• Office Energy: Energy efficiency in your San Francisco base of operations.
• Waste Management: Minimizing paper use in administrative and clinical trial processes.

The global digital therapeutics market is projected to be worth around $\text{\$17.6}$ billion in 2025, according to one estimate, showing massive growth in the sector you inhabit, which means even small operational efficiencies scale up in importance.

Indirect Sustainability Through Product Use

This is where your real environmental leverage lies. Your product is designed to change behavior for cardiometabolic diseases like Type 2 Diabetes, which means it directly supports sustainability by reducing the need for in-person, travel-intensive clinical visits. Think about the reduction in carbon emissions from patients driving to and from appointments, or even the energy used by physical clinics.

The potential for this indirect benefit is huge, especially as the $\text{DTx}$ sector continues to mature; investments in $\text{DTx}$ were expected to surge by $\text{26.7\%}$ year over year between 2020-2025. If $\text{BTTX}$'s solution achieves broad adoption, the cumulative reduction in patient travel could be substantial. What this estimate hides, however, is the actual patient adherence rate needed to displace a physical visit.

The positive environmental contribution is tied to:

• Reducing patient travel for routine check-ins.
• Potentially reducing unnecessary physical diagnostic testing.
• Enabling remote monitoring, which is inherently less resource-intensive.

Electronic Waste and Device Compatibility

Since your product runs on consumer devices-smartphones and tablets-you must prioritize energy efficiency and device compatibility to reduce electronic waste generation. A poorly optimized app drains a user's battery faster, indirectly contributing to the device's overall energy consumption and potentially shortening its useful life, pushing users toward earlier replacement.

Design must focus on lightweight code and efficient data transfer. For instance, if your application requires constant, high-bandwidth data streaming, the environmental cost shifts to the network infrastructure. Conversely, if you can streamline data synchronization, you help mitigate this.

Here is a comparison of potential impacts:

Factor	Direct Impact (Low for $\text{BTTX}$)	Indirect Impact (High Potential for $\text{BTTX}$)
Manufacturing Waste	Near zero (Software only)	N/A
Patient Travel Emissions	N/A	Significant reduction potential via remote care
Device Lifespan/E-Waste	Low (Efficient coding helps)	Moderate (Battery drain from inefficient software)
Data Center Energy Use	Low to Moderate (Cloud dependent)	N/A

ESG Profile Weighting

To be defintely clear, $\text{BTTX}$'s overall Environmental, Social, and Governance ($\text{ESG}$) profile is heavily weighted toward the 'Social' component. The entire premise of a $\text{PDT}$ for chronic disease management is improving patient health access and outcomes-that's a massive 'S' factor win. The 'E' factor is secondary and mostly about responsible digital operation.

You should track metrics that reflect this weighting. While I don't have $\text{BTTX}$'s specific 2025 $\text{ESG}$ data, a peer in the digital health space might report on things like:

• Percentage reduction in paper records converted to electronic systems.
• Estimated patient travel miles avoided due to remote therapy.
• Energy efficiency benchmarks for the application per active user session.

Finance: draft 13-week cash view by Friday.